Integrating AI tools into drug discovery introduces a mix of opportunities and challenges for startups and large pharmaceutical companies. These challenges often center on intellectual property (IP) risks, licensing...more
1/15/2025
/ Acquisitions ,
Artificial Intelligence ,
Documentation ,
Due Diligence ,
Innovation ,
Intellectual Property Protection ,
IP License ,
Life Sciences ,
Mergers ,
Patents ,
Pharmaceutical Industry ,
Risk Management ,
Startups
AI is poised to revolutionize drug discovery, but uncertainty in developing protectable IP in this emerging field creates a host of potential risks for companies innovating in this space. Further complicating things: not all...more
The scientific benefits and legal risks of AI-driven drug discovery are consequential. But recent IP law decisions allude to a general concept that IP rights will not be awarded if AI completely or significantly replaces...more
AI is shaving years off the drug-discovery process. But it’s not just leaving other research modalities in the dust—the law itself is struggling to keep up, especially when it comes to patenting AI-aided drug discovery....more
6/14/2024
/ Artificial Intelligence ,
Inventors ,
Life Sciences ,
Machine Learning ,
Patents ,
Pharmaceutical Industry ,
Research and Development ,
Risk Assessment ,
Risk Management ,
Startups ,
Strategic Planning ,
USPTO
AI is vaulting drug discovery forward leaps and bounds—and now regulators are beginning to catch up, with the United States Patent and Trademark Office recently issuing new guidelines on the patentability of AI-assisted...more